ARDTArdent Health, Inc.
Ardent Health, Inc. (ARDT) operates as a regional healthcare provider, delivering inpatient and outpatient services across mid-sized U.S. urban communities. The company’s next catalyst is November 9, 2026 — Q3 2026 Earnings Release, which will test its ability to sustain revenue growth and manage margin pressures amid a competitive and regulatory-heavy environment .
- Revenue grew 6.0% YoY to $6.45B, with net income of $73.12M and free cash flow of $416.07M (TTM).
- Net margin remains thin at 1.1%, with debt-to-equity of 0.88x.
- Free cash flow has been a consistent outperformer, but scaling is constrained by geographic and operational limits.
The Read
Ardent Health's stock historically showed a median absolute move of ~6%.
The schedule
- Mon9Nov
The earnings release will test whether Ardent Health can deliver consistent revenue and margin improvements, particularly in light of recent guidance updates and the impact of CMS policy changes. The last print showed mixed results, with guidance revisions overshadowing actual performance.
- Tue9Feb
This release will test the company's ability to sustain revenue growth and margin expansion after the Q3 results. The focus will be on the impact of CMS policy changes and the effectiveness of cost-cutting measures. The last print showed a mixed performance, with guidance revisions overshadowing actual results.
- Wed5May
The Q1 2027 earnings release will test the company's ability to maintain momentum from the previous quarter and deliver on its guidance. The focus will be on the impact of CMS policy changes and the effectiveness of cost-cutting measures. The last print showed a mixed performance, with guidance revisions overshadowing actual results.
- Mon9Aug
This release will test the company's ability to sustain revenue growth and margin expansion after the Q1 results. The focus will be on the impact of CMS policy changes and the effectiveness of cost-cutting measures. The last print showed a mixed performance, with guidance revisions overshadowing actual results.
Past
- Wed9Sep
Actual outcome: Bear · $10.63 at outcome
Ardent Health's stock fell 4.6% following the participation in the i News Event, missing the bull target and falling below the bear floor. The event did not generate positive momentum, and the stock remained below the bear floor, indicating a bearish outcome.
Participation in i News Event
- Wed2Sep
Actual outcome: Mixed · $10.72 at outcome
Ardent Health's stock fell 1.5% following the participation in the i News Event, as the market reacted to mixed signals. While the company showcased strategic partnerships and long-term growth initiatives, these were overshadowed by underwhelming financial results and cautious guidance. The stock settled below the bear floor, reflecting investor concerns about near-term performance and uncertainty around execution.
Participation in i News Event
- Mon10Aug
Actual outcome: Mixed · $10.92 at outcome
Ardent Health reported Q2 earnings of $0.12 per share, matching the Zacks Consensus Estimate, but the stock fell 1.4% following the earnings release. The mixed results, combined with the recent addition to the Zacks Strong Sell List and negative sentiment around the options market, pressured the stock, leading to a bearish outcome.
Ardent Health's Q2 print will clarify whether Q1's resilient earnings trend and the recent Fujifilm partnership are translating into sustained margin expansion.
- Wed5Aug
Actual outcome: Bull · $11.09 at outcome
Although the anticipated CMS IPPS rule was in focus, Ardent Health's Q2 earnings release dominated the narrative. The company reported an EPS miss of $0.12 versus the $0.17 estimate due to weaker volumes, but the stock reached the bull target as management highlighted that cost controls, favorable payer contract renewals, and strong cash flow effectively offset the shortfall.
Under President Trump's administration, the Centers for Medicare & Medicaid Services (CMS) is scheduled to release the final 2027 Inpatient Prospective Payment System (IPPS) rule, dictating Medicare reimbursement rates.
- Thu18Jun
Actual outcome: Bull · $9.35 at outcome
The stock rose 5.1% through the outcome date and eventually surpassed the $9.80 bull target. While there were no major headlines directly addressing the class action status conference, positive sentiment was supported by a recent insider purchase from Director Robert DeMichiei and the company's presentation at the Goldman Sachs Global Healthcare Conference.
Initial status conference and lead plaintiff appointment for the consolidated securities fraud lawsuits stemming from the Q4 2025 accounting write-off.
- Wed6May
Actual outcome: Bull · $9.95 at outcome
Ardent Health reported Q1 2026 EPS of $0.28, exactly meeting analyst estimates, and highlighted year-over-year growth with steady operational and financial performance. Following the previous quarter's accounting write-off and legal concerns, these stable results reassured investors, driving a 6.2% rally as the market gained confidence in the company's underlying fundamentals.
Ardent Health reports Q1 2026 earnings, its first print since the $97M Q4 accounting write-off and subsequent securities fraud lawsuits. The market will focus heavily on cash flow metrics and legal reserves.
- Mon16Mar
Actual outcome: Bear · $8.46 at outcome
The stock fell 8.7% following the Q4 2025 earnings release and 2026 guidance, despite an EPS beat. The guidance suggested weaker-than-expected revenue growth and margin pressure, which overshadowed the earnings beat. The market reacted negatively to the lack of optimism in the forward outlook, leading to the bearish price action.
- Sun15Mar
Actual outcome: Bull · $10.14 at outcome
Ardent Health reached the bull target of $9.40 as the stock remained resilient despite federal scrutiny on hospital pricing and a flurry of class-action lawsuit deadlines. Analyst sentiment remained constructive with a majority of 'Buy' or 'Hold' ratings, suggesting that the market viewed the regulatory risks as manageable and the company's transparency compliance as sufficient to maintain its valuation.
